NEW YORK, Might 07, 2021 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM) is becoming a member of Psychological Well being America (MHA) and different advocacy organizations in observing Might is Psychological Well being Month, by elevating consciousness of and supporting individuals dwelling with despair, nervousness, and different psychological well being circumstances. MHA is the nation’s main community-based nonprofit group devoted to addressing the wants of these dwelling with psychological sickness and selling general psychological well being.
Latest information from the Facilities for Illness Management (CDC) and from MHA point out a putting improve within the prevalence of psychological well being circumstances within the U.S., together with a greater than 4-fold improve in signs of despair in comparison with previous to the COVID-19 pandemic:
- The prevalence of despair signs elevated from 6.5% in 2019 to a excessive of 30.2% of U.S. adults in December 2020 [1,2];
- The prevalence of hysteria signs elevated from 8.1% in 2019 to a excessive of 36.9% of U.S. adults in December 2020 [1,2];
- Of the almost 3 million individuals who took an MHA psychological well being screening through the previous 12 months, roughly 1 million have been experiencing despair, and tons of of 1000’s extra have been experiencing both nervousness or psychosis ; and
- Previous to the COVID-19 pandemic, an estimated 1 in 5 adults within the U.S. reported dwelling with a psychological well being situation, together with despair, nervousness, bipolar dysfunction, schizophrenia, and post-traumatic stress dysfunction . Analysis exhibits that estimate has grown to not less than 2 in 5 adults .
These findings spotlight the necessity, greater than ever, to advertise psychological well being consciousness, improve entry to care, and supply assist for these dwelling with psychological well being circumstances.
People dwelling with psychological well being circumstances will not be alone. The next organizations are dedicated to offering assist and sources to individuals dwelling with psychological well being circumstances, and to these trying to prioritize their psychological well being:
- Psychological Well being America (MHA) (https://www.mhanational.org). MHA’s work is pushed by its dedication to advertise psychological well being as a vital a part of general wellness, together with prevention providers for all; early identification and intervention for these in danger; and built-in care, providers, and assist for individuals who want them, with restoration because the aim. Assets offered by the MHA embody a free on-line psychological well being display, which could be discovered at MHAscreening.org, to assist determine indicators of psychological well being issues.
- The Despair and Bipolar Assist Alliance (DBSA) (https://www.dbsalliance.org). DBSA is a number one nationwide peer-focused psychological well being group, whose mission is to supply hope, assist, assist, and training for people who stay with temper issues.
- Nervousness and Despair Affiliation of America (ADAA) (https://adaa.org). ADAA’s mission focuses on bettering high quality of life for these with nervousness, despair, OCD, PTSD, and co-occurring issues via training, observe, and analysis.
As a part of Axsome’s dedication to despair training, sources and instruments can be found at www.talkdepressettling.com to assist assist these affected by despair.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical firm creating novel therapies for the administration of central nervous system (CNS) issues for which there are restricted therapy choices. For the many individuals dealing with unsatisfactory remedies for CNS issues, Axsome accelerates the invention and adoption of life-changing medicines. For extra info, please go to the Firm’s web site at www.axsome.com. The Firm might often disseminate materials, nonpublic info on the corporate web site.
- Terlizzi EP, Schiller JS. Estimates of psychological well being symptomatology, by month of interview: United States, 2019. Nationwide Heart for Well being Statistics. (2021). Retrieved from https://www.cdc.gov/nchs/information/nhis/mental-health-monthly-508.pdf.
- US Census Bureau Family Pulse Survey 2020-2021. Retrieved from https://www.cdc.gov/nchs/covid19/pulse/mental-health.htm.
- Psychological Well being America. (2021). Psychological Well being Month 2021 Toolkit. Retrieved from https://mhanational.org/websites/default/recordsdata/MHM 2021 – Foreword and Intro.pdf.
- Substance Abuse and Psychological Well being Providers Administration. (2020). Outcomes from the 2019 Nationwide Survey on Drug Use and Well being. Retrieved from https://www.samhsa.gov/data/.
- Czeisler MÉ, et al. Psychological Well being, Substance Use, and Suicidal Ideation Through the COVID-19 Pandemic — United States, June 24–30, 2020. Retrieved from https://www.cdc.gov/mmwr/volumes/69/wr/mm6932a1.htm?s_cid=mm6932a1_w.
Ahead Trying Statements
Sure issues mentioned on this press launch are “forward-looking statements”. We might, in some circumstances, use phrases corresponding to “predicts,” “believes,” “potential,” “proceed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “might,” “may,” “may,” “will,” “ought to” or different phrases that convey uncertainty of future occasions or outcomes to determine these forward-looking statements. Specifically, the Firm’s statements relating to developments and potential future outcomes are examples of such forward-looking statements. The forward-looking statements embody dangers and uncertainties, together with, however not restricted to, the success, timing and price of our ongoing scientific trials and anticipated scientific trials for our present product candidates, together with statements relating to the timing of initiation, tempo of enrollment and completion of the trials (together with our means to completely fund our disclosed scientific trials, which assumes no materials adjustments to our at present projected bills), futility analyses and receipt of interim outcomes, which aren’t essentially indicative of the ultimate outcomes of our ongoing scientific trials, and the quantity or kind of research or nature of outcomes essential to assist the submitting of a brand new drug software (“NDA”) for any of our present product candidates; our means to fund extra scientific trials to proceed the development of our product candidates; the timing of and our means to acquire and keep U.S. Meals and Drug Administration (“FDA”) or different regulatory authority approval of, or different motion with respect to, our product candidates (together with, however not restricted to, whether or not potential submitting points or points recognized by FDA through the substantive evaluation might impression the potential approvability of the Firm’s NDA submission for AXS-05 in MDD or the timing of such approval, and whether or not the FDA will agree with the Firm’s discontinuation of the bupropion therapy arm of the ADVANCE examine in accordance with the unbiased information monitoring committee’s suggestions); the profitable submission of and approval by the FDA of an NDA for AXS-07 for the acute therapy of migraine in adults with or with out aura, pursuant to our particular protocol evaluation for the MOMENTUM scientific trial; the potential for the ASCEND scientific trial, mixed with the GEMINI scientific trial outcomes, to supply a foundation for approval of AXS-05 for the therapy of main depressive dysfunction and speed up its growth timeline and business path to sufferers; the Firm’s means to efficiently defend its mental property or receive the required licenses at a price acceptable to the Firm, if in any respect; the profitable implementation of the Firm’s analysis and growth packages and collaborations; the success of the Firm’s license agreements; the acceptance by the market of the Firm’s product candidates, if accredited; the Firm’s anticipated capital necessities, together with the quantity of capital required for the Firm’s business launch of its product candidates, and the potential impression on the Firm’s anticipated money runway; in addition to unexpected circumstances or different disruptions to regular enterprise operations arising from or associated to COVID-19; and different components, together with common financial circumstances and regulatory developments, not throughout the Firm’s management. The components mentioned herein may trigger precise outcomes and developments to be materially totally different from these expressed in or implied by such statements. The forward-looking statements are made solely as of the date of this press launch and the Firm undertakes no obligation to publicly replace such forward-looking statements to replicate subsequent occasions or circumstance.
Chief Working Officer
Axsome Therapeutics, Inc.
22 Cortlandt Avenue, 16th Ground
New York, NY 10007
Electronic mail: email@example.com